Anti-inflammatory activities of a new VEGF blocker, Conbercept

Background Angiogenesis and inflammation exhibit a mutually reinforcing relationship in many human diseases. Vascular endothelial growth factor (VEGF) is one of the most important proangiogenic mediators. Conbercept is a novel VEGF inhibitor. Method Type II collagen-induced rat rheumatoid arthritis (CIA) model was established to evaluate the anti-chronic inflammation activities of Conbercept. ELISA was used to measure the concentrations of immune factors in the blood of arthritis rats. The xylene-induced ear edema was conducted to evaluate the effect of Conbercept on acute inflammation. Result and discussion Our results showed that Conbercept significantly reduced the paw edema volume and the arthritis index in CIA rats. Furthermore, we found that Conbercept decreased the serum levels of vascular endothelial growth factor (VEGF), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6) in CIA rats. Xylene-induced ear edema is a widely used method to study acute inflammation. Conbercept significantly inhibited xylene-induced ear edema. Conclusion All results indicate that Conbercept exhibits significant inhibition of acute and chronic inflammation.

Automated summary

The study demonstrates that Conbercept significantly reduces paw edema volume and arthritis index in CIA rats, and decreases serum levels of VEGF, TNF-alpha, and IL-6. Additionally, Conbercept inhibits xylene-induced ear edema, indicating its significant impact on acute and chronic inflammation.